These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31512109)

  • 1. Retrospective Analysis of Bioanalytical Method Validation Approaches in Biosimilar Biological Product Development.
    Obianom ON; Thway TM; Schrieber SJ; Okusanya OO; Wang YM; Huang SM; Zineh I
    AAPS J; 2019 Sep; 21(6):105. PubMed ID: 31512109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Perspectives on Ligand-Binding Assay Practices in the Quantification of Circulating Therapeutic Proteins for Biosimilar Biological Product Development.
    Thway TM; Wang YM; Booth BP; Maxfield K; Huang SM; Zineh I
    AAPS J; 2019 Dec; 22(1):15. PubMed ID: 31858313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs.
    Colbert A; Umble-Romero A; Prokop S; Chow VF; Wong T; DeSimone D; Zhou L; Pederson S
    MAbs; 2014; 6(5):1178-89. PubMed ID: 25517303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considerations in the early development of biosimilar products.
    Li EC; Abbas R; Jacobs IA; Yin D
    Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Path Towards a Tailored Clinical Biosimilar Development.
    Schiestl M; Ranganna G; Watson K; Jung B; Roth K; Capsius B; Trieb M; Bias P; Maréchal-Jamil J
    BioDrugs; 2020 Jun; 34(3):297-306. PubMed ID: 32266678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Japanese regulation of biosimilar products: past experience and current challenges.
    Arato T
    Br J Clin Pharmacol; 2016 Jul; 82(1):30-40. PubMed ID: 26987746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory watch: Innovation in biologic new molecular entities: 1986-2014.
    Miller KL; Lanthier M
    Nat Rev Drug Discov; 2015 Feb; 14(2):83. PubMed ID: 25633785
    [No Abstract]   [Full Text] [Related]  

  • 9. Perspectives on the Current State of the Biosimilar Regulatory Pathway in the United States.
    Dougherty MK; Zineh I; Christl L
    Clin Pharmacol Ther; 2018 Jan; 103(1):36-38. PubMed ID: 29152721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytic characterization of biosimilars.
    Sullivan PM; DiGrazia LM
    Am J Health Syst Pharm; 2017 Apr; 74(8):568-579. PubMed ID: 28389456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development.
    Cai XY; Gouty D; Baughman S; Ramakrishnan M; Cullen C
    Bioanalysis; 2011 Mar; 3(5):535-40. PubMed ID: 21388266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations for Biologic Product Drug-Drug Interactions: A Regulatory Perspective.
    Schrieber SJ; Pfuma-Fletcher E; Wang X; Wang YC; Sagoo S; Madabushi R; Huang SM; Zineh I
    Clin Pharmacol Ther; 2019 Jun; 105(6):1332-1334. PubMed ID: 30844077
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
    O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
    Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices.
    Stergiopoulos S; Getz K
    Drug Saf; 2015 Aug; 38(8):687-92. PubMed ID: 26108298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 - Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62).
    Piccoli S; Mehta D; Vitaliti A; Allinson J; Amur S; Eck S; Green C; Hedrick M; Hopper S; Ji A; Joyce A; Litwin V; Maher K; Mathews J; Peng K; Safavi A; Wang YM; Zhang Y; Amaravadi L; Palackal N; Thankamony S; Beaver C; Bame E; Emrich T; Grimaldi C; Haulenbeek J; Joyce A; Kakkanaiah V; Lanham D; Maher K; Mayer A; Trampont PC; Vermet L; Dakappagari N; Fleener C; Garofolo F; Rogers C; Tangri S; Xu Y; Liang M; Rajadhyaksha M; Richards S; Schweighardt B; Purushothama S; Baltrukonis D; Brumm J; Cherry E; Delcarpini J; Gleason C; Kirshner S; Kubiak R; Pan L; Partridge M; Pedras-Vasconcelos J; Qu Q; Skibeli V; Saunders TS; Staack RF; Stubenrauch K; Torri A; Verthelyi D; Yan H; Gorovits B; Palmer R; Milton M; Long B; Corsaro B; Farrokhi V; Fiscella M; Henderson N; Jawa V; McNally J; Murphy R; Waldner H; Yang TY
    Bioanalysis; 2019 Dec; 11(24):2207-2244. PubMed ID: 31820675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-Based Approach for Analytical Comparability and Comparability Protocols.
    Iyer KR; Lequeux I
    PDA J Pharm Sci Technol; 2020; 74(5):563-570. PubMed ID: 32295861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demonstrating biosimilar and originator antidrug antibody binding comparability in antidrug antibody assays: a practical approach.
    Ryding J; Stahl M; Ullmann M
    Bioanalysis; 2017 Sep; 9(18):1395-1406. PubMed ID: 28920451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter--Draft FDA Guidance "Considerations in Demonstrating Interchangeability with a Reference Product": Overview and Presentation-Related Concerns.
    Rubinstein E
    J Manag Care Spec Pharm; 2017 Mar; 23(3):266. PubMed ID: 28230453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A survey of pharmacokinetic bioanalytical methods in biosimilar biological license applications for the assessment of target and antidrug antibody effects.
    Hackel DT; Thway TM; Huang SM; Wang YC
    Bioanalysis; 2021 Sep; 13(17):1323-1332. PubMed ID: 34515515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products.
    Kwon O; Joung J; Park Y; Kim CW; Hong SH
    Biologicals; 2017 Jul; 48():101-108. PubMed ID: 28495312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.